{"product_id":"coherus-business-model-canvas","title":"Coherus Biosciences Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCoherus Biosciences: Business Model Unveiled!\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Coherus Biosciences's business model. This in-depth Business Model Canvas reveals how the company drives value through biosimilar development and captures market share in the pharmaceutical industry. Ideal for entrepreneurs and investors looking for actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations (CMOs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCoherus Biosciences relies on specialized Contract Manufacturing Organizations (CMOs) for the large-scale production of its biosimilar products. These partnerships are vital for maintaining high manufacturing quality, ensuring a dependable supply chain, and adhering to rigorous regulatory requirements in global markets.  For instance, in 2024, Coherus continued its established relationships with CMOs to support the commercial launch and ongoing supply of its key products like UDENYCA® (pegfilgrastim-cbkb) and CIMERLI® (bevacizumab-bvfr).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCoherus Biosciences actively seeks research and development collaborators, often partnering with leading academic institutions and innovative biotech companies. These alliances are crucial for advancing early-stage discovery and integrating cutting-edge technologies into their biosimilar pipeline. For instance, collaborations can provide access to specialized expertise in areas like protein engineering or advanced analytical techniques, significantly speeding up the development cycle.\u003c\/p\u003e\n\u003cp\u003eThese strategic partnerships are designed to enhance the scientific foundation of Coherus' biosimilar candidates. By leveraging external knowledge and novel platforms, the company can accelerate the identification of promising drug targets and refine the manufacturing processes. This collaborative approach is vital for maintaining a competitive edge in the rapidly evolving biosimilar market, ensuring the scientific validity and efficacy of their products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistribution and Commercialization Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCoherus Biosciences actively pursues distribution and commercialization alliances to expand its market penetration. These partnerships are crucial for accessing diverse geographies and patient populations, leveraging established sales networks and local market knowledge. \u003c\/p\u003e\n\u003cp\u003eFor instance, in 2024, Coherus announced a strategic partnership with a leading pharmaceutical distributor in Europe, aiming to accelerate the rollout of its biosimilar products across key member states. This alliance allows Coherus to tap into the partner's extensive infrastructure and regulatory expertise, facilitating efficient product delivery and market adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Clinical Research Organizations (CROs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCoherus Biosciences relies heavily on strategic partnerships with Regulatory and Clinical Research Organizations (CROs) to navigate the intricate landscape of biosimilar development. These collaborations are fundamental for the efficient and compliant execution of clinical trials, a critical phase for any biosimilar candidate. CROs bring specialized knowledge in trial design, patient recruitment, and rigorous data analysis, which are all vital for a successful regulatory submission.\u003c\/p\u003e\n\u003cp\u003eThese partnerships are instrumental in ensuring that Coherus' biosimilar candidates meet stringent regulatory requirements and timelines. For instance, in 2024, the biosimilar market continued its expansion, with regulatory bodies like the FDA approving several new biosimilars, underscoring the importance of expert CRO guidance. Coherus' engagement with CROs allows them to effectively manage the complexities of these trials, from initial protocol development to final data reporting, thereby accelerating the path to market for their products.\u003c\/p\u003e\n\u003cp\u003eKey aspects of these partnerships include:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpertise in Regulatory Compliance:\u003c\/strong\u003e CROs ensure adherence to Good Clinical Practice (GCP) and other global regulatory standards, minimizing risks of non-compliance.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEfficient Trial Management:\u003c\/strong\u003e CROs manage operational aspects of trials, including site selection, patient recruitment, and data collection, optimizing timelines and resource allocation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eData Integrity and Analysis:\u003c\/strong\u003e They provide robust data management and statistical analysis, crucial for demonstrating biosimilarity and safety to regulatory agencies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNavigating Complex Pathways:\u003c\/strong\u003e CROs offer strategic guidance on regulatory submissions, increasing the likelihood of timely approvals for biosimilar products.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Provider Networks and Group Purchasing Organizations (GPOs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCoherus Biosciences actively cultivates relationships with healthcare provider networks and Group Purchasing Organizations (GPOs). These collaborations are instrumental in gaining access to formularies and negotiating favorable purchasing terms for their biosimilar products.\u003c\/p\u003e\n\u003cp\u003eThese partnerships are crucial for Coherus to boost the uptake of its biosimil offerings. By working with these established entities, Coherus can ensure that its more affordable therapeutic options reach a broader patient base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eGPO Partnerships:\u003c\/strong\u003e Coherus leverages GPOs to streamline access and procurement for numerous hospitals and healthcare systems, potentially increasing market penetration for its biosimil drugs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNetwork Agreements:\u003c\/strong\u003e Securing agreements with major provider networks helps Coherus ensure its biosimil products are considered and prescribed within large patient populations.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCost-Effective Access:\u003c\/strong\u003e The company's strategy focuses on making biosimil treatments accessible and affordable, with these key partnerships acting as a vital conduit for achieving this goal.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnerships Propel Biosimilar Market Success\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCoherus Biosciences strategically partners with Contract Manufacturing Organizations (CMOs) for biosimilar production, ensuring quality and supply chain reliability. In 2024, these CMO relationships were critical for the commercialization of UDENYCA® and CIMERLI®.\u003c\/p\u003e\n\u003cp\u003eThe company also engages with academic institutions and biotech firms for R\u0026amp;D collaborations, accelerating pipeline development through access to specialized expertise. These alliances enhance the scientific foundation of their biosimilar candidates.\u003c\/p\u003e\n\u003cp\u003eDistribution and commercialization partnerships are key for market penetration, leveraging established sales networks and local knowledge. A 2024 European distribution agreement exemplifies this strategy.\u003c\/p\u003e\n\u003cp\u003eFurthermore, Coherus collaborates with Regulatory and Clinical Research Organizations (CROs) to manage complex clinical trials and navigate regulatory submissions, crucial for timely market entry, especially given the growing biosimilar approvals in 2024.\u003c\/p\u003e\n\u003cp\u003ePartnerships with healthcare provider networks and Group Purchasing Organizations (GPOs) are vital for formulary access and favorable purchasing terms, driving the uptake of Coherus' cost-effective biosimilar treatments.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCoherus Biosciences' business model focuses on developing and commercializing high-quality, affordable biosimilar biologics to address unmet patient needs and reduce healthcare costs.\u003c\/p\u003e\n\u003cp\u003eIt leverages strategic partnerships for development and manufacturing, targeting key therapeutic areas with strong market potential and a clear regulatory pathway.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCoherus Biosciences' Business Model Canvas acts as a pain point reliever by providing a clear, one-page snapshot of their strategy, enabling rapid understanding and identification of how they address market needs in the biosimilar space.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilar Product Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiosimilar product research and development at Coherus Biosciences is a rigorous scientific undertaking. It involves detailed analytical characterization to confirm the biosimilar is highly similar to the reference biologic, alongside extensive preclinical testing and comprehensive clinical trials. These trials are crucial for demonstrating comparable efficacy and safety in patients.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Coherus continued its commitment to this area, focusing on advancing its pipeline. For instance, the company's efforts in developing biosimilars for established biologics aim to provide more affordable treatment options. The market for biosimilars is rapidly expanding, with global sales projected to reach hundreds of billions of dollars in the coming years, highlighting the significance of these R\u0026amp;D activities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCoherus Biosciences’ manufacturing and supply chain management focuses on overseeing the production of its biosimilar products. This often involves partnering with third-party contract manufacturing organizations (CMOs) to ensure strict quality control and compliance with Good Manufacturing Practices (GMP).  For instance, in 2023, Coherus continued its collaboration with CMOs for its key products like Udenyca and CIMERLI, essential for maintaining product integrity and regulatory standards.\u003c\/p\u003e\n\u003cp\u003eEffective supply chain management is paramount for Coherus to guarantee consistent product availability and timely delivery to patients and healthcare providers across its target markets. This operational efficiency is crucial for capturing market share and building trust in its biosimilar offerings.  The company’s ability to manage its supply chain robustly directly impacts its revenue generation and market penetration strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Submissions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA crucial activity for Coherus Biosciences involves expertly navigating the intricate regulatory pathways across various global markets to secure approvals for its biosimilar products. This encompasses the meticulous preparation and submission of extensive dossiers to key health authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). \u003c\/p\u003e\n\u003cp\u003eThe company also actively manages ongoing post-market surveillance obligations, ensuring continued compliance and product lifecycle management. For instance, in 2023, Coherus continued its focus on regulatory submissions, aiming to expand its portfolio and reach new patient populations. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization, Sales, and Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFollowing regulatory approval, Coherus Biosciences focuses intensely on commercializing its biosimilars. This includes a robust strategy to introduce these products to the market, targeting key stakeholders in the healthcare ecosystem.\u003c\/p\u003e\n\u003cp\u003eThe company invests in building and maintaining a specialized sales force. This team is crucial for engaging healthcare providers and educating them about the clinical and economic benefits of Coherus' biosimilar offerings.\u003c\/p\u003e\n\u003cp\u003eMarketing efforts are designed to raise awareness and drive adoption. This involves developing educational materials and campaigns aimed at physicians, pharmacists, payers, and patient advocacy groups, highlighting the value proposition of biosimilars.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Access and Reimbursement:\u003c\/strong\u003e Coherus actively engages with payers to secure favorable formulary placement and reimbursement for its biosimilars, a critical step for commercial success.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePhysician Education:\u003c\/strong\u003e The company's medical affairs and sales teams work to educate healthcare professionals on the scientific evidence supporting the efficacy and safety of their biosimilar products.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatient Advocacy Engagement:\u003c\/strong\u003e Building relationships with patient advocacy groups helps Coherus communicate the importance of biosimilar availability and affordability for patients.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSales Force Deployment:\u003c\/strong\u003e In 2024, Coherus continued to leverage its dedicated sales force to promote its approved biosimilars, aiming to capture market share against originator biologics.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Management and Legal Defense\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCoherus Biosciences actively manages its intellectual property by strategically patenting its biosimilar portfolio. This is a crucial activity to secure market exclusivity and protect the substantial investments made in research and development.\u003c\/p\u003e\n\u003cp\u003eThe company also engages in defending its intellectual property rights against challenges from originator companies. For instance, in 2024, Coherus continued to navigate patent landscapes for its key biosimilars, such as UDENYCA (pegfilgrastim-cbkb) and CIMERLI (biosimilar trastuzumab-qyjp).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatent Protection:\u003c\/strong\u003e Coherus continuously files patents to shield its biosimilar products, ensuring a competitive edge.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLitigation Defense:\u003c\/strong\u003e The company actively defends against patent litigation initiated by originator drug manufacturers, a common occurrence in the biosimilar market.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eR\u0026amp;D Safeguard:\u003c\/strong\u003e Protecting intellectual property is vital to recouping the significant financial outlays involved in bringing biosimilars to market.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvancing Biosimilars: Pipeline to Market Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCoherus Biosciences' key activities revolve around the entire lifecycle of biosimilar products, from initial research and development to market launch and ongoing management. This includes rigorous scientific validation, navigating complex regulatory approvals, and implementing effective commercialization strategies. A significant part of their operation is also dedicated to protecting their intellectual property through patent filings and defense.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Coherus remained focused on advancing its biosimilar pipeline and commercializing its approved products. The company's commitment to R\u0026amp;D is evident in its efforts to bring more affordable treatment options to market, capitalizing on the rapidly growing global biosimilar market, which is expected to reach substantial figures in the coming years. Their manufacturing relies on partnerships with contract manufacturing organizations (CMOs) to ensure high-quality production and compliance with stringent regulatory standards like GMP.\u003c\/p\u003e\n\u003cp\u003eCommercialization activities are robust, involving a specialized sales force to educate healthcare providers on the clinical and economic advantages of their biosimilars. Market access and reimbursement efforts are critical, as Coherus actively works with payers to secure favorable placement and coverage for their products. Patient advocacy engagement also plays a role in communicating the benefits of biosimilars.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eKey Activity\u003c\/th\u003e\n\u003cth\u003eDescription\u003c\/th\u003e\n\u003cth\u003e2024 Focus\/Data Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Development\u003c\/td\u003e\n\u003ctd\u003eDeveloping highly similar biosimilars to reference biologics, involving analytical characterization and clinical trials.\u003c\/td\u003e\n\u003ctd\u003eAdvancing pipeline products, aiming for more affordable treatment options.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing \u0026amp; Supply Chain\u003c\/td\u003e\n\u003ctd\u003eOverseeing production, often with CMO partnerships, ensuring quality and GMP compliance.\u003c\/td\u003e\n\u003ctd\u003eMaintaining consistent product availability and timely delivery.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Affairs\u003c\/td\u003e\n\u003ctd\u003eSecuring approvals from health authorities like the FDA and EMA through dossier submissions.\u003c\/td\u003e\n\u003ctd\u003eContinued focus on regulatory submissions for portfolio expansion.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercialization\u003c\/td\u003e\n\u003ctd\u003eLaunching and promoting biosimilars through sales forces, marketing, and market access strategies.\u003c\/td\u003e\n\u003ctd\u003eLeveraging dedicated sales force to capture market share for approved biosimilars.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntellectual Property Management\u003c\/td\u003e\n\u003ctd\u003ePatenting biosimilar portfolios and defending against patent challenges.\u003c\/td\u003e\n\u003ctd\u003eNavigating patent landscapes for key biosimilars like UDENYCA and CIMERLI.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Coherus Biosciences Business Model Canvas you are previewing is the actual, complete document you will receive upon purchase. This isn't a sample or a mockup; it's a direct representation of the final deliverable, providing full insight into their strategic framework.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your purchase, you will gain instant access to this exact Business Model Canvas, ready for your analysis and application. You can be assured that the content and structure you see here are precisely what will be delivered, ensuring transparency and immediate utility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55674849231225,"sku":"coherus-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/coherus-business-model-canvas.png?v=1755796698","url":"https:\/\/portersfiveforce.com\/products\/coherus-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}